QSIAWHIGH SIGNALRISK10-K

QSIAW faces mounting financial distress with cash declining 56% to $21.6M while simultaneously warning that their critical Proteus platform launch could materially impact long-term viability if delayed or underperforms.

The company is burning through cash rapidly while betting heavily on a single product launch (Proteus) scheduled for end of 2026, creating significant execution risk. The explicit warning that failure to deliver Proteus on time or with promised capabilities "could materially impact any potential of long-term financial success and our market credibility" suggests this is a make-or-break moment for the company.

Comparing 2026-03-03 vs 2025-03-03View on EDGAR →
FINANCIAL ANALYSIS

QSIAW's financial position deteriorated significantly with revenue declining 20% to $2.4M and cash reserves plummeting 56% to $21.6M, while current liabilities increased 27% to $23.0M. The company reduced capital expenditures by 45% and cut SG&A expenses by 11%, indicating aggressive cost-cutting measures. This financial profile suggests a company in distress mode, conserving cash while hoping their upcoming Proteus platform launch can reverse the declining trajectory.

FINANCIAL STATEMENT CHANGES
Accounts Receivable
Balance Sheet
-57.9%
$1.3M→$561K

Receivables declined — improved collection efficiency or conservative revenue recognition.

Cash & Equivalents
Balance Sheet
-56.1%
$49.2M→$21.6M

Cash declined 56.1% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

Capital Expenditure
Cash Flow
-45.1%
$4.6M→$2.5M

Capex reduced 45.1% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Gross Profit
P&L
-27.9%
$1.6M→$1.2M

Gross margin compression — rising input costs, pricing pressure, or unfavorable product mix shift.

Current Liabilities
Balance Sheet
+26.6%
$18.2M→$23.0M

Current liabilities rose 26.6% — increased short-term obligations, watch current ratio.

Total Liabilities
Balance Sheet
-21.8%
$32.5M→$25.4M

Liabilities reduced 21.8% — deleveraging improves balance sheet strength and financial flexibility.

Inventory
Balance Sheet
-21.4%
$4.1M→$3.2M

Inventory reduced 21.4% — lean inventory management or demand outpacing supply.

Revenue
P&L
-20.3%
$3.1M→$2.4M

Revenue softened 20.3% — monitor whether this is cyclical or structural.

Current Assets
Balance Sheet
-19.3%
$218.0M→$175.9M

Current assets declined 19.3% — monitor working capital adequacy and short-term liquidity.

SG&A Expense
P&L
-11.4%
$50.5M→$44.8M

SG&A reduced 11.4% — improved cost efficiency or headcount reduction improving operating margins.

LANGUAGE CHANGES
NEW — 2026-03-03
PRIOR — 2025-03-03
ADDED
As of February 25, 2026 , the registrant had 196,431,273 shares of Class A common stock outstanding and 19,937,500 shares of Class B common stock outstanding.
The development and launch of new products may slow or stop existing product revenue in anticipation of superior technology that is pending launch.
Our Proteus TM platform ( Proteus ) is anticipated to be commercially available by the end of 2026, with an expectation of customer-focused applications and capabilities.
If Proteus is not launched within our communicated time frame, or is delivered without the customer-focused applications and capabilities, it could materially impact any potential of long-term financial success and our market credibility.
Our use of artificial intelligence and machine learning is subject to evolving laws and regulations and risks associated with unauthorized use, and may not result in the competitive advantages desired, all of which could expose us to competitive risk and legal liability.
If these manufacturers should fail or not perform satisfactorily, or for economic or other reasons choose to end business with us, our ability to commercialize and supply our instruments and consumable offerings would be adversely affected.
We have limited experience producing and supplying our products, and we may be unable to consistently manufacture or source our instruments and consumables to the necessary specifications or in quantities necessary to meet demand on a timely basis and at acceptable performance and cost levels.
Risks Related to Our Securities and to Being a Public Company Our outstanding warrants became exercisable for our Class A common stock in September 2021, which increased the number of shares eligible for future resale in the public market and could result in dilution to our stockholders if exercised.
We are a life sciences company focused on proteomics research, with the mission of transforming single-molecule analysis and democratizing its use by providing researchers and clinicians access to the proteome, the set of proteins expressed within a cell.
We have developed a proprietary, universal, single-molecule detection platform that we are applying to proteomics to enable next-gen protein sequencing ( NGPS ) to sequence proteins in a massively parallel fashion (rather than sequentially, one at a time), which can also be used for the study of nucleic acids.
REMOVED
As of February 26, 2025 , the registrant had 163,202,105 shares of Class A common stock outstanding and 19,937,500 shares of Class B common stock outstanding.
All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the foregoing cautionary statements.
If these manufacturers should fail or not perform satisfactorily, our ability to commercialize and supply our instruments and consumable offerings would be adversely affected.
Our internal manufacturing equipment is specialized with limited vendor options and long lead times.
Patent terms may be inadequate to protect our competitive position on our products for an adequate amount of time.
We are a life sciences company focused on the development and commercialization of proteomics research tools, with the mission to bring single-molecule proteomics analysis to every lab, everywhere.
We have developed a proprietary universal single-molecule detection platform that we are initially applying to proteomics to enable Next-Generation Protein Sequencing TM ( NGPS ).
Traditionally, proteomic workflows to sequence proteins have several limitations including low throughput (only one protein at a time), requires the use of hazardous chemicals, is time consuming and labor intensive requiring days or weeks of a scientist s time to complete.
NGPS delivers single amino acid level resolution, using a low cost, low maintenance instrument and includes a suite of automated data analysis tools so that any lab, with modest scientific expertise, can easily implement protein sequencing into their workflows.
Our products include instrumentation (Platinum and Platinum Pro), consumable kits for library preparation and sequencing for use with our instruments and a suite of automated data analysis tools.
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →